SCHEMBL26547775

SCHEMBL26547775

Cc1cc2c(OS(=O)(=O)C(F)(F)F)cc(C3CCOCC3)cc2n(C)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.40
DRD1 P21728 6/20 0.40
DRD4 P21917 6/20 0.40
DRD5 P21918 6/20 0.40
DRD3 P35462 6/20 0.40
BRD4 O60885 4/20 0.34
BRPF1 P55201 3/20 0.34
TAF1 P21675 1/20 0.34
BRD2 P25440 1/20 0.34
EP300 Q09472 1/20 0.34
BRD3 Q15059 1/20 0.34
BRDT Q58F21 1/20 0.34
CREBBP Q92793 1/20 0.34
CECR2 Q9BXF3 1/20 0.34
BRD9 Q9H8M2 1/20 0.34
BAZ2B Q9UIF8 1/20 0.34
BAZ2A Q9UIF9 1/20 0.34
PDE1B Q01064 2/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29471189 1.00 DRD2 (0.40) DRD2DRD1DRD4DRD5DRD3
SCHEMBL26547777 0.94 DRD2 (0.39) DRD2DRD1DRD4DRD5DRD3
SCHEMBL31426135 0.89 TLR9 (0.38) DRD2DRD1DRD4DRD5DRD3
SCHEMBL31426275 0.88 DRD2 (0.37) DRD2DRD1DRD4DRD5DRD3
SCHEMBL31425970 0.83 DRD2 (0.40) DRD2DRD1DRD4DRD5DRD3
SCHEMBL29471279 0.82 BRD4 (0.41) BRD4BRPF1BRD2BRD9PDE1B
SCHEMBL26111817 0.82 BRD4 (0.41) BRD4BRPF1BRD2BRD9PDE1B
SCHEMBL31542325 0.82 KDM4E (0.41) DRD2DRD1DRD4DRD5DRD3
SCHEMBL30480903 0.81 KDM4E (0.34) BRD4BRPF1BAZ2AKDM4EALDH1A1
SCHEMBL26547751 0.81 KDM4E (0.34) BRD4BRPF1BAZ2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed
CN-116368128-A Heterocyclic compounds as CBP/EP300 bromodomain inhibitors 奥瑞基尼肿瘤有限公司 2023-06-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 DRD2 4411/4885DRD1 4650/4885DRD4 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.